Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Roivant will sell its potential blockbuster ulcerative colitis drug to Roche for $7.1 billion, less than a year after acquiring it from Pfizer for what …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Roivant flips ul­cer­a­tive col­i­tis drug to Roche for $7.1B, less than a year af­ter get­ting the drug from Pfiz­er

Senior Editor

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer